Overview

Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder

Status:
RECRUITING
Trial end date:
2027-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy and safety of tirzepatide in adults with obesity and binge-eating disorder, comparing tirzepatide against placebo and lisdexamfetamine dimesylate. All participants will receive guided self-help cognitive behavioral therapy.
Phase:
PHASE2
Details
Lead Sponsor:
Johns Hopkins University
Collaborator:
Eli Lilly and Company
Treatments:
Injections
Lisdexamfetamine Dimesylate
Tirzepatide